Eric Richman

Eric Richman has worked at a variety of companies since 2008. Eric began their career as a Director at ADMA Biologics, Inc. in 2008. In 2010, they took on the role of President & CEO and Director at PharmAthene, Inc. In 2016, they became a Venture Partner at Brace Pharma Capital and a Director and CEO at Tyrogenex. In 2017, they were an Independent Director at LabConnect. In 2018, they became an Independent Director at NovelStem International Corp. and a Director at ZyVersa Therapeutics Inc. In 2019, they were a Director at NeuBase Therapeutics, Inc. and a Director & Co-Founder at Horizon Infusions / InFuse Holdings. Eric is currently a Director at Gain Therapeutics.

Eric Richman completed their Bachelor's degree in Biomedical Science from CUNY Medical School Sophie Davis School of Biomedical Education between 1980 and 1985. Eric then went on to complete their Master's degree in Business Administration, with a focus in Finance and International Marketing, from Thunderbird School of Global Management between 1986 and 1987.